Recursion to Acquire Exscientia for $688M in AI-Powered Deal
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
- Latest
- Trending
Recursion Pharmaceuticals acquires Exscientia to enhance AI drug discovery, potentially saving millions in drug development costs.
Despite the growth of OpenAI, participants doubt that Google will dominate the AI market like it did with search. While ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.